Effect of topical hydrocortisone 0.335% (Softacort®) on ocular surface inflammation in patients with dry eye

Registry ID

EUCTR2017-003285-27

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Laboratoires Thea

Start date

2017-09-26

Completion date

2018-11-28

Last update

2026-08-16

Conditions

• Dry Eye Disease

Summary

To evaluate the clinical efficacy of Softacort (Hydrocortisone 0.335%) in chronic dry eye patients with ocular surface inflammation using two different treatment regimes.

Locations

• , , Austria

Related clinical trials

• Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
• Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops
• Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
• Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease
• A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.
• 2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

View on source registry